GlaxoSmithKline Historical Cash Flow
| GSK Stock | USD 33.70 0.35 1.05% |
Analysis of GlaxoSmithKline PLC cash flow over time is an excellent tool to project GlaxoSmithKline PLC ADR future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 1.4 B or Other Non Cash Items of 491.4 M as it is a great indicator of GlaxoSmithKline PLC ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining GlaxoSmithKline PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlaxoSmithKline PLC ADR is a good buy for the upcoming year.
GlaxoSmithKline |
About GlaxoSmithKline Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in GlaxoSmithKline balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which GlaxoSmithKline's non-liquid assets can be easily converted into cash.
GlaxoSmithKline PLC Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by GlaxoSmithKline PLC ADR to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of GlaxoSmithKline PLC operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in GlaxoSmithKline PLC ADR financial statement analysis. It represents the amount of money remaining after all of GlaxoSmithKline PLC ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from GlaxoSmithKline PLC's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At this time, GlaxoSmithKline PLC's Other Non Cash Items is quite stable compared to the past year. Dividends Paid is expected to rise to about 3.4 B this year, although the value of Free Cash Flow will most likely fall to about 3.4 B.
GlaxoSmithKline PLC cash flow statement Correlations
Click cells to compare fundamentals
GlaxoSmithKline PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GlaxoSmithKline PLC cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 300M | 119M | 25M | (269M) | (424M) | (402.8M) | |
| Change In Cash | 744M | 431M | (1.4B) | (394M) | (567M) | (538.7M) | |
| Free Cash Flow | 5.9B | 6.2B | 5.0B | 5.1B | 4.0B | 3.4B | |
| Change In Working Capital | 531M | 120M | (473M) | 271M | (364M) | (345.8M) | |
| Begin Period Cash Flow | 4.1B | 4.8B | 5.3B | 3.8B | 3.4B | 2.2B | |
| Other Cashflows From Financing Activities | (194M) | 122M | 27M | 8.9B | (1.0B) | (982.3M) | |
| Depreciation | 3.0B | 624M | 2.5B | 2.3B | 2.3B | 1.4B | |
| Other Non Cash Items | 814M | 848M | 756M | (433M) | 468M | 491.4M | |
| Capital Expenditures | 2.2B | 2.2B | 2.9B | 2.3B | 2.3B | 1.5B | |
| Total Cash From Operating Activities | 8.0B | 8.4B | 8.0B | 7.4B | 6.8B | 4.9B | |
| Net Income | 5.3B | 6.4B | 5.1B | 4.9B | 4.9B | 4.6B | |
| Total Cash From Financing Activities | (1.8B) | (10.1B) | (7.6B) | 823M | (5.6B) | (5.4B) | |
| End Period Cash Flow | 4.8B | 5.3B | 3.8B | 3.4B | 2.9B | 2.1B | |
| Dividends Paid | 4.0B | 4.0B | 4.0B | 3.5B | 2.2B | 3.4B | |
| Sale Purchase Of Stock | 10.3B | 999M | (1.6B) | 25M | (197M) | (206.9M) | |
| Change To Account Receivables | (953.8M) | (224M) | (782M) | (158M) | (649M) | (616.6M) | |
| Stock Based Compensation | 365M | 381M | 367M | 346M | 307M | 335.4M | |
| Investments | (5.4B) | 2.2B | 334M | (8.8B) | (1.6B) | (1.5B) | |
| Net Borrowings | 3.5B | (4.2B) | (2.2B) | (4.8B) | (5.5B) | (5.8B) | |
| Total Cashflows From Investing Activities | (5.4B) | 2.2B | (1.8B) | (8.8B) | (1.6B) | (1.7B) | |
| Change To Operating Activities | (160M) | (159M) | 1.3B | (1.4B) | (1.3B) | (1.2B) | |
| Change To Netincome | 670M | 380M | 105M | (8.3B) | (9.6B) | (10.1B) | |
| Change To Liabilities | 263M | 225M | 284M | 494M | 568.1M | 596.5M | |
| Issuance Of Capital Stock | 51M | 29M | 21M | 25M | 10M | 9.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.